Cutting-edge biomarker technologies are enabling faster, more accurate cancer diagnosis and tailored therapies, revolutionizing precision oncology.
Cutting-edge biomarker technologies are enabling faster, more accurate cancer diagnosis and tailored therapies, revolutionizing precision oncology.
With a blockbuster IPO on the horizon, Australian biotech innovation is drawing global eyes and fresh capital to …
With a first-in-class oral treatment approved, atopic dermatitis patients gain a novel option for disease management and improved …
A new multinational clinical trial marks a significant step in developing transformative gene therapies for rare inherited disorders.
Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
Moderna pushes the boundaries of mRNA therapy into rare genetic diseases, aiming for transformative treatments.
Manufacturing breakthroughs are set to transform cell therapy production, paving the way for faster trials and wider patient …
Australian-led clinical trials are advancing the future of diabetes care with oral insulin innovations.
New partnerships in real-time genomics promise faster, more accurate diagnoses for pediatric rare diseases.
New device approval and robust oncology funding highlight ongoing biopharma momentum in cancer therapies.
Already a subscriber? Log in